Research & Development

Carrick licenses global rights to BTG’s ovarian cancer drug

Carrick Therapeutics has acquired global licensing rights to develop and commercialize BTG’s ovarian cancer drug BTG945, which has been renamed as CT900.

Mundipharma buys Spanish biosimilars company Cinfa Biotech

Mundipharma, a global network of privately-owned independent associated companies, has acquired Spanish biosimilars development company Cinfa Biotech from Infarco for an undisclosed price.

Neurocrine Biosciences, Jnana Therapeutics to discover medicines for CNS disorders

Neurocrine Biosciences and Jnana Therapeutics have entered into a research collaboration to discover novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders.

Sitryx launches with $30m funding to develop disease-modifying therapeutics

New biopharmaceutical company Sitryx has been launched with $30m fundraising for the development of disease modifying therapeutics in immunometabolism.

Arrowhead, Janssen sign $3.7bn license and collaboration deal

Biopharmaceutical firm Arrowhead Pharmaceuticals has signed a license and collaboration agreement with Janssen Pharmaceuticals for the development and commercialization of hepatitis B virus (HBV) treatment, ARO-HBV.

Boston Pharmaceuticals buys Novartis’ three anti-infective drug candidates

Boston Pharmaceuticals has signed a licensing and equity agreement with Novartis for the worldwide rights to three of the latter's anti-infective candidates for the potential treatment of Gram-negative infections.

Kite, HiFiBiO to develop technology for discovery of neoantigen-reactive TCRs to treat cancer

Gilead firm Kite and HiFiBiO Therapeutics have entered into a research collaboration and license agreement to develop technology for the discovery of neoantigen-reactive T cell receptors (TCRs) to treat various cancers such as solid tumors.

Kala Pharmaceuticals raises $110m financing to achieve significant milestones

Us biopharma company Kala Pharmaceuticals has closed a $110m credit facility with funds managed by healthcare focused investment firm Athyrium Capital Management.

Cancer startup GO Therapeutics signs $195m licensing deal with Roche

GO Therapeutics has signed a license agreement with Roche for new glycotargeting bispecific cancer treatment.